Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) — Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), announced today that data from a Phase 1 pilot trial (see NCT03560752) evaluating the potential safety, immunological response and efficacy of the cytomegalovirus (“CMV”) vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic […]
StemBioSys Announces Launch of NeuroMatrix™, a Technological Leap Forward in Laboratory Production of Functionally Mature Human Neural Cell Types
SAN ANTONIO, Feb. 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types. StemBioSys designed NeuroMatrix™ to expand the use of iPSC-derived neurons in drug discovery and toxicity testing. “NeuroMatrix™ represents a breakthrough in hiPSC-derived neuronal development […]
Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines
CAMBRIDGE, Mass., Jan. 31, 2023 /PRNewswire/ — Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus Bio, pairing their technologies to resolve challenges related to the delivery of complex genetic materials to living human cells. “Gene-modified cell therapies hold great promise for patients. […]
How Banking Umbilical Cord Stem Cells Could Save Your Child’s Life with Kathryn Cross
The placenta and cord blood are often discarded after birth, but they contain valuable stem cells that can be preserved for future medical use. Placental and cord blood banking allows families to store these cells, which can be used to treat a range of diseases and conditions later in life. From leukemia to sickle cell […]
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”), in New […]
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK). The Phase […]
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn’s Phase 3 ALS Study
NEW YORK, Jan. 10, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn’s placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community. The specimens are being submitted to the […]
Dr. Jill interviews Dr. Chadwick Prodromos on Stem Cell Treatment and Regenerative Medicine
In episode #136, Dr. Jill Carnahan speaks with Dr. Chadwick Prodromos about the exciting developments in stem cell treatment and how it is revolutionizing our approach to disease and aging. Stem cells have the unique ability to develop into any type of cell in the body, making them a promising tool for repairing and regenerating […]
FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies
MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and […]
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT. A live webcast of […]